Wickramasekara: Benchling AI saved a customer an 8-month redundant mouse study
Sajith Wickramasekara · No Priors Ep. 140 | With Benchling Co-Founder and CEO Sajith Wickramasekara · Nov 13, 2025 · at 17:36
Sajith Wickramasekara is the CEO of Benchling. He explains how Benchling's research agent surfaced forgotten legacy data from an acquired company's lab notebooks.
0:00 / 0:29exact quote · 29.5s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“We had a customer that was getting ready to run some mouse studies, and they were looking at 20 different mouse models, and they used a deep research our deep research capability to look at all the historical mouse studies that they had run, and it turned out that a bunch of the mouse models that they were about to, like, investigate, which would have taken eight months, huge cost, big experiment to run someone had already done before, and it was trapped in some lab notebook from, you know, many years ago from a company that had been bought And all the people were long gone.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Sajith Wickramasekara
Wickramasekara: Major pharma increasingly licenses drug molecules from China
“We've seen this huge uptick in pharma going to China and buying molecules that they typically would have bought from American biotechs.”
Wickramasekara: Clinical trial optimization is a red herring versus molecule quality
“People get very focused on clinical trials because they're like the biggest line item. And they're important, don't get me wrong, but I think it's actually a bit of a red, red herring. Where, ah, yes, there are operational problems. Like, some studies are desi…”
Wickramasekara: GLP-1s will probably be the best-selling drugs of all time
“And then all of a sudden, like we have this category defining medicine that's going to go on to probably be the best selling drug of all, all time.”
Wickramasekara: AI in scientific discovery will focus on augmentation over autonomy next 1-2 years
“While I would love for that to happen, and I'm maybe more optimistic on a longer time scale, we will get there. I think in the short term, I'm next one to two years, which, you know, already feels like an eternity in AI time. I'm a little bit more bullish on s…”
Wickramasekara: Most Biotech Researchers Are Not Yet Using Much AI in R&D
“Most people aren't really using that much AI and R&D yet. They all want to, they're primed to, but there's a lot of concerns about accuracy, IP, security, legal. And I think the farther you go from SF, the like, Larger those concerns, concerns get.”
Wickramasekara: Pure AI biology model companies must morph into biopharma
“I think it's unlikely, it's possible, but it's unlikely that sort of, hey, they're just gonna remain pure model companies who just do deals with pharma, where pharma, you know, pays them a hundred million dollars upfront or something like that, and they have f…”